dimethyl (2-oxo-3-cyclopentylpropyl)-phosphonate | 87929-28-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: dimethyl (2-oxo-3-cyclopentylpropyl)-phosphonate
• 英文别名: dimethyl 3-cyclopentyl-2-oxopropylphosphonate；Dimethyl (3-cyclopentyl-2-oxopropyl)phosphonate；1-cyclopentyl-3-dimethoxyphosphorylpropan-2-one
• CAS: 87929-28-0
• 化学式: C₁₀H₁₉O₄P
• 分子量: 234.232
• InChiKey: SEGZWFLFMRLEAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  dimethyl (2-oxo-3-cyclopentylpropyl)-phosphonate 在 硼烷四氢呋喃络合物 、 水 、 sodium hydride 、 sodium hydroxide 、 (R)-2-甲基-CBS-恶唑硼烷 作用下， 以 四氢呋喃 、 乙二醇二甲醚 为溶剂， 生成 2-[2-[(2R)-2-[(3S)-4-cyclopentyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl]ethylsulfanyl]-1,3-thiazole-4-carboxylic acid
  参考文献：
  名称：

  Discovery of a novel EP2/EP4 dual agonist with high subtype-selectivity

  摘要：

  A series of gamma-lactam prostaglandin E(1) analogs bearing a 16-phenyl moiety in the omega-chain and aryl moiety in the alpha-chain were synthesized and biologically evaluated. Among the tested compounds, gamma-lactam PGE analog 3 designed as a structural hybrid of 1 and 2 was discovered as the most optimized EP2/EP4 dual agonist with excellent subtype-selectivity (K(i) values: mEP2 = 9.3 nM, mEP4 = 0.41 nM). A structure-activity relationship study is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.109
• 作为产物：
  描述：

  环戊基乙酸甲酯 、 甲基膦酸二甲酯 在 正丁基锂 作用下， 以 甲苯 为溶剂， 生成 dimethyl (2-oxo-3-cyclopentylpropyl)-phosphonate
  参考文献：
  名称：

  Discovery of a novel EP2/EP4 dual agonist with high subtype-selectivity

  摘要：

  A series of gamma-lactam prostaglandin E(1) analogs bearing a 16-phenyl moiety in the omega-chain and aryl moiety in the alpha-chain were synthesized and biologically evaluated. Among the tested compounds, gamma-lactam PGE analog 3 designed as a structural hybrid of 1 and 2 was discovered as the most optimized EP2/EP4 dual agonist with excellent subtype-selectivity (K(i) values: mEP2 = 9.3 nM, mEP4 = 0.41 nM). A structure-activity relationship study is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.109

文献信息

• 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 derivatives
  申请人：Toray Industries, Inc.

  公开号：US04775692A1

  公开（公告）日：1988-10-04

  Disclosed herein are novel prostaglandin I.sub.2 (PGI.sub.2) derivatives exhibiting excellent in vivo duration and activities, said derivatives being represented by the general formula: ##STR1## wherein R.sub.1, X, R.sub.2 and R.sub.3 are as defined herein.

  本文披露了一种展现出优异体内持续时间和活性的新型前列腺素I.sub.2（PGI.sub.2）衍生物，所述衍生物由以下一般式表示：##STR1##其中R.sub.1、X、R.sub.2和R.sub.3如本文所定义。
• Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors
  申请人：Amrein Kurt

  公开号：US20080009499A1

  公开（公告）日：2008-01-10

  Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof for use as pharmaceutical compositions.

  化合物的化学式（I）：以及其药用可接受的盐和酯，用作药物组合物。
• Carbacyclin compounds; pharmaceutical compositions and method of use
  申请人：Sankyo Company, Limited

  公开号：US05405870A1

  公开（公告）日：1995-04-11

  Compounds of formula (Ic): ##STR1## having valuable platelet-aggregation inhibitory activities useful for the prophylaxis and treatment of such diseases as thrombosis and pharmaceutical compositions containing said compounds.

  化合物的公式(Ic): ##STR1## 具有有价值的血小板聚集抑制活性，可用于预防和治疗血栓等疾病，并含有该化合物的药物组合物。
• 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0232776A2

  公开（公告）日：1987-08-19

  Disclosed herein are novel prostaglandin I2 (PGI2) derivatives exhibiting excellent in vivo duration and acitivities, said derivatives being represented by the general formula: wherein R1, X, R2 and R3 are as defined herein.

  本文公开了新型前列腺素 I2 (PGI2) 衍生物，其在体内的持续时间和活性极佳，所述衍生物由通式表示： 其中 R1、X、R2 和 R3 如本文所定义。
• ALKYL-PYRIDAZINE DERIVATIVES AS INHIBITORS OF 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1(11B-HSD 1)
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2044034A1

  公开（公告）日：2009-04-08